Business Context and Reporting Period
This Form 8-K was filed by Anzu Special Acquisition Corp I, a special purpose acquisition company, regarding the closing of its initial public offering on March 4, 2021. The filing does not identify Envoy Medical, Inc. as the registrant or provide operating information about Envoy Medical.
Key Financial Metrics and Capitalization
| Item | Reported amount |
|---|---|
| IPO units sold | 42,000,000 |
| IPO price per unit | $10.00 |
| IPO gross proceeds | $420.0 million |
| Private placement warrants sold | 12,400,000 |
| Private placement proceeds | Approximately $12.4 million |
| Amount placed in trust | $420.0 million |
| Deferred underwriter discount included in trust proceeds | Approximately $14.7 million |
| Warrant terms | Each whole warrant is exercisable for one share of Class A common stock at $11.50 per share, subject to adjustments |
Each IPO unit consisted of one share of Class A common stock and one-third of one warrant. The filing provides no revenue, operating profit, net income, cash-flow, margin, debt, or liquidity metrics beyond the IPO and trust-account amounts.
Material Changes Versus Prior Period
This was a financing and formation-related report. No comparable prior-period operating results are presented. The principal change was the completion of the IPO and related private placement, with $420.0 million deposited into a U.S.-based trust account.
Guidance, Outlook, Risks, and Unusual Items
- The underwriters received a 45-day option to purchase up to 6,300,000 additional units at the IPO price.
- The sponsor agreed to purchase up to 1,260,000 additional private placement warrants if the over-allotment option is exercised.
- The filing does not provide acquisition-target guidance, financial forecasts, management outlook, or discussion of operating risks.
- An audited balance sheet as of March 4, 2021 was filed as Exhibit 99.1.
Investor Verification Items
- Verify the registrant identity: the supplied filing names Anzu Special Acquisition Corp I, while the request metadata names Envoy Medical, Inc.
- Review Exhibit 99.1 for the audited post-closing balance sheet and the accounting treatment of IPO and warrant proceeds.
- Confirm the status and potential dilution from the 45-day over-allotment option and private placement warrants.
- Review the company’s subsequent filings for any business combination, target-company announcement, trust-account restrictions, or redemption terms.